Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of CTX001 in β-thalassemia or Sickle Cell Disease
NCT04208529Phase 3Enrolling by invitation
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Sep 2039
- Modality
- Gene Silencing, CRISPR-Cas9, Cell Therapies
- Countries
- 6
01
Overview
A Phase 3 trial of exagamglogene autotemcel in beta thalassemia, sickle cell disease (SCD), sponsored by Vertex Pharmaceuticals. Started Jan 2021; status: enrolling by invitation.
02
Drugs
exagamglogene autotemcel
03
Conditions
beta thalassemiasickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04208529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208529.